Owned by the Association for International Promotion & Study in Tumors (APSIT)
Aptamer-functionalized triptolide with release controllability as a promising targeted therapy against triple-negative breast cancer
Targeted delivery and precise release of toxins is a prospective strategy for the treatment of triple-negative breast cancer (TNBC), yet the flexibility to incorporate both properties simultaneously remains tr...